Sign in
Not yet taking people in United StatesPhase 4

Congenital Syphilis Treatment Trial (CONSISTENT) in Neonates

Key facts

Who runs it
University of Alabama at Birmingham
Where
Albuquerque, Birmingham, Dallas, Houston, Mobile, Orange, Philadelphia, Shreveport, Sioux Falls, St Louis, and Tampa, United StatesSee the 11 sites
Trial code
Status
Not yet recruiting
Phase
Phase 4
People taking part
374 people, planned
Started
1 Nov 2026
Expected to end
31 Aug 2031
Type of study
Interventional, 2 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • Benzathine Penicillin
  • Amoxicillin
Record updated
2 September 2026

Who can take part

Age
0 days to 30 days
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 12 criteriaShow less

Who can take part

  • Confirmed staged maternal syphilis in pregnancy with rapid plasma reagin (RPR) + and T. pallidum hemagglutination antibody (TPHA) or other evidence of active syphilis (i.e. ulcerative anogenital lesion with positive darkfield microscopy or PCR+ for T. pallidum)
  • Inadequate therapy (non-BPG regimen, incomplete regimen for stage, <30 days prior to delivery), undocumented therapy, or lack of maternal syphilis therapy in pregnancy
  • Infant age ≤ 30 days old
  • Gestational age at birth ≥35 weeks
  • Infant birth weight ≥ 750 grams
  • Infant tolerating oral feeds
  • Normal infant examination, laboratory, and radiographic evaluation: hemoglobin, platelet count, CSF (cell count, protein, VDRL), long-bone radiographs
  • Infant quantitative RPR reactive and ≤ 4-fold lower titer compared with maternal RPR
  • Parent(s) or legal guardian(s) capable and willing to provide informed consent

Who cannot take part

  • Uncontrolled maternal HIV (viral load >1000 copies/mL at or within 4 weeks of delivery) or HIV-exposed infants who require three drug antiretroviral post exposure prophylaxis
  • Unable to ensure infant follow up through six months of age
  • Infant receipt of antibiotics between birth and enrollment with activity against T. pallidum (including beta-lactam, cephalosporin, or azithromycin)

Where in United States

  • University of New MexicoAlbuquerque, United StatesContact: Martha Muller, MDNot yet recruiting
  • University of Alabama at BirminghamBirmingham, United StatesContact: Jodie Dionne, MDNot yet recruiting
  • University of Texas Southwestern Medical Center at DallasDallas, United StatesContact: Amanda Evans, MDNot yet recruiting
  • Baylor College of Medicine/ Texas Children's HospitalHouston, United StatesContact: Ryan Rochat, MDNot yet recruiting
  • University of South Alabama Medical CenterMobile, United StatesContact: Manimaran Ramani, MDNot yet recruiting
  • Children's Hospital of Orange CountyOrange, United StatesContact: Negar Ashouri, MDNot yet recruiting
  • Children's Hospital of PhiladelphiaPhiladelphia, United StatesContact: Torsten Joerger, MDNot yet recruiting
  • LSU Health Sciences Center-ShrevportShreveport, United StatesContact: Patricia Pichilingue-Reto, MDNot yet recruiting
  • Avera McKennan University Health CenterSioux Falls, United StatesContact: Peter Lim, MDNot yet recruiting
  • Washington University St. LouisSt Louis, United StatesContact: Carol Kao, MDNot yet recruiting
  • University of South FloridaTampa, United StatesContact: Claudia Espinosa, MDNot yet recruiting

About the trial

What the trial wants to find out

The Investigator hypothesize that the treatment efficacy will be similar in both study arms. Secondary outcomes and endpoints will characterize safety by comparing adverse events (AEs), tolerability, and adherence to therapy in each arm.

Read full original descriptionShow less

This is a Phase 4, open-label, multicenter trial designed to evaluate the efficacy of a single injected dose of intramuscular (IM) BPG (Arm 1) compared to oral amoxicillin administered twice daily (BID) for 10 days (Arm 2). The study will involve infants aged ≤ 30 days old with suspected untreated syphilis. The trial will be conducted at 12 sites across the U.S., enrolling approximately 374 participants.

Upon randomization, participants will undergo baseline study sample collection (blood, oropharyngeal, and nasal mucosal swabs for PCR testing) and then receive either treatment with oral amoxicillin or IM BPG, both with directly observed therapy. The participant enrolled in the optional pharmacokinetic (PK) sub-study will have additional blood samples collected for PK analysis within the first 24-48 hours after treatment. Participants will be discharged from the hospital following routine procedures, with the oral amoxicillin dosing continued at home (BID) by the caregiver.

The 2 groups in the trial

  • Single Dose of BPGExisting treatment, for comparison

    Neonates will receive a single dose of BPG as standard of care.

    Treatment: Benzathine Penicillin

  • Study Medication (Amoxicillin)Treatment being tested

    Neonates will receive Amoxicillin (Study Medication), twice a day for 10 days.

    Treatment: Amoxicillin

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Congenital Syphilis Treatment Trial (CONSISTENT): Phase IV, Open-label, Randomized Controlled Trial of Amoxicillin vs. Benzathine in Neonates With Possible Congenital Syphilis
Record updated
2 September 2026